News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Red-Hot Alexion (ALXN) Is Only Suitable For Risk Takers Now



1/12/2017 7:09:13 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
For a company that lost its chief executive and chief financial officer in rapid succession, Alexion Pharmaceuticals (ALXN) has managed to miraculously weather the storm, and its shares have shot higher as a result.

After losing about 35% last year, shares have rebounded by more than 17% so far in 2017.

Investors are clearly ready to overlook the company's failures, in particular the botched clinical trial for its top-selling medical product, Soliris. The trial investigated complications around post-operative scenarios following kidney transplants.

Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES